Clinical trial of letrozole for postmenopausal patients with bone metastasis in breast cancer
- VernacularTitle:来曲唑治疗绝经后乳腺癌骨转移
- Author:
Fan FAN
;
Xiang-Hua WAN
;
Hong XIA
;
Al ET
- Publication Type:Journal Article
- Keywords:
breast neoplasm;
bone metastasis;
letrozole
- From:China Oncology
2001;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose: To evaluate the efficacy and adverse effects of letrozole for postmenopausal breast cancer patients with bone raetastases. Methods: Thity-six breast cancer patients with bone metstases received 2. 5 mg tablet letrozole every day. for at least two months. Results: In the 36 patients who were evaluable for efficacy and toxicity, the complete response rate (CR) , partial response rate ( PR) , disease stabilization rate ( SD) and progressive disease rate ( PD) were respectively 5.5% , 22. 2% , 55. 5% and 16. 6% . The clinical benefit rate ( CR + PR + SD ≥ 6 months ) was 58. 3% (21/36) with 11 patients (30. 5%) having SD for at least 6 months . Conclusions: Letrozole is a well tolerated agent with reasonable efficacy but low toxicity for postmenopausal breast cancer patients with bone metastases.
